

# Min Hwan Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3159370/publications.pdf>

Version: 2024-02-01

45  
papers

430  
citations

840776  
11  
h-index

794594  
19  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1037  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. <i>Lung Cancer</i> , 2014, 83, 389-395.	2.0	63
2	Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Lung Cancer</i> , 2014, 84, 196-202.	2.0	53
3	Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death Ligand 1 Blockade Responses. <i>Hepatology</i> , 2021, 74, 1914-1931.	7.3	48
4	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK rearranged lung cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10581.	6.9	40
5	MK5 Regulates YAP Stability and Is a Molecular Target in YAP-Driven Cancers. <i>Cancer Research</i> , 2019, 79, 6139-6152.	0.9	24
6	Ifosfamide-induced Fanconi syndrome with diabetes insipidus. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 246.	1.7	18
7	Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response. <i>British Journal of Cancer</i> , 2020, 122, 1649-1660.	6.4	17
8	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. <i>Apmis</i> , 2017, 125, 223-229.	2.0	15
9	Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. <i>Oncologist</i> , 2019, 24, e1108-e1114.	3.7	15
10	Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1271.	7.1	15
11	FOXP3 Expression Is Related to High Ki-67 Index and Poor Prognosis in Lymph Node-Positive Breast Cancer Patients. <i>Oncology</i> , 2013, 85, 128-136.	1.9	14
12	Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 687-697.	2.5	13
13	Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110359.	3.2	13
14	Anaplastic Lymphoma Kinase Gene Copy Number Gain in Inflammatory Breast Cancer (IBC): Prevalence, Clinicopathologic Features and Prognostic Implication. <i>PLoS ONE</i> , 2015, 10, e0120320.	2.5	12
15	Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 689587.	2.8	11
16	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 819-831.	3.0	10
17	EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E Mutant NSCLC Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1627-1636.	4.1	8
18	Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 443-454.	4.2	8

#	ARTICLE	IF	CITATIONS
19	Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 3096.	3.7	7
20	A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4161-TPS4161.	1.6	4
21	Genomic landscape of extraordinary responses in metastatic breast cancer. <i>Communications Biology</i> , 2021, 4, 449.	4.4	3
22	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3113-3113.	1.6	3
23	Cytomegalovirus Colitis with Colon Perforation and Lower Gastrointestinal Bleeding in a Immunocompetent Patient. <i>The Ewha Medical Journal</i> , 2014, 37, 105.	0.2	2
24	A man with recurrent hypovolemic shock on anti-“programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy. <i>European Journal of Cancer</i> , 2018, 104, 104-107.	2.8	2
25	Can We Prevent Resistance to Osimertinib? Combination or Sequential. <i>Journal of Thoracic Oncology</i> , 2018, 13, 877-879.	1.1	2
26	Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 107-116.	2.5	2
27	Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, , .	2.6	2
28	Successful Sirolimus Treatment of Multiple Visceral Kaposi's Sarcoma in a Renal Allograft Patient. <i>The Journal of the Korean Society for Transplantation</i> , 2012, 26, 293.	0.2	1
29	Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2405.	3.7	1
30	Copy number aberration burden on circulating tumor DNA predicts recurrence risk after neoadjuvant chemotherapy in patients with triple-negative breast cancer: Post-hoc analysis of phase III PEARLY trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 603-603.	1.6	1
31	A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1098-1098.	1.6	1
32	Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4096-4096.	1.6	1
33	On-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1066-1066.	1.6	0
34	Abstract 2053: Molecular characterization of BRCA1 c.5339T>C missense mutation in DNA damage response of triple-negative breast cancer cells. , 2021, , .		0
35	Everolimus-associated pneumonitis in Asian metastatic renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15596-e15596.	1.6	0
36	Protective effect of bisphosphonate on the cortical bone at key locations of the femur in aromatase inhibitor-associated bone loss: A three-dimensional cortical bone mapping study. <i>Journal of Bone Oncology</i> , 2022, 32, 100409.	2.4	0

#	ARTICLE	IF	CITATIONS
37	A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, TPS624-TPS624.	1.6	0
38	Abstract P2-12-13: Pathologic complete response rate according to the carboplatin dose in patients with non-metastatic HER2+ breast cancer treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP). Cancer Research, 2022, 82, P2-12-13-P2-12-13.	0.9	0
39	Abstract P1-18-32: A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG) Tj ETQq1 1 0.7843140gBT /Over	0.9	0
40	Abstract P1-17-09: Efficacy of limited dose modifications for palbociclib-related grade 3 neutropenia in hormone receptor positive metastatic breast cancer. Cancer Research, 2022, 82, P1-17-09-P1-17-09.	0.9	0
41	Abstract P1-19-03: Phase II trial of durvalumab and tremelimumab in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean cancer study group trial (KCSG BR17-04). Cancer Research, 2022, 82, P1-19-03-P1-19-03.	0.9	0
42	Abstract PD6-07: Whole genome sequencing-based circulating tumor DNA profiling of metastatic breast cancer patients for molecular characterization and therapy response prediction. Cancer Research, 2022, 82, PD6-07-PD6-07.	0.9	0
43	Abstract P2-13-14: Pattern of recurrence after pathologic complete response after neoadjuvant chemotherapy in patients with early HER2-positive breast cancer: Real-world evidence. Cancer Research, 2022, 82, P2-13-14-P2-13-14.	0.9	0
44	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. Journal of Clinical Oncology, 2022, 40, e14557-e14557.	1.6	0
45	Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group (KCSG).. Journal of Clinical Oncology, 2022, 40, e18759-e18759.	1.6	0